Get the Stockscreener App
3.7272
4.39%
-0.1428
Grace Therapeutics Inc stock is traded at $3.7272, with a volume of 246.91K.
It is down -4.39% in the last 24 hours and up +6.32% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
See More
Previous Close:
$3.87
Open:
$3.86
24h Volume:
246.91K
Relative Volume:
2.20
Market Cap:
$57.25M
Revenue:
-
Net Income/Loss:
$-10.31M
P/E Ratio:
-4.8405
EPS:
-0.77
Net Cash Flow:
$-12.65M
1W Performance:
-10.19%
1M Performance:
+6.32%
6M Performance:
+15.62%
1Y Performance:
+30.28%
1-Day Range:
$3.58
$3.86
1-Week Range:
$3.58
$4.30
52-Week Range:
$1.75
$4.30
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
3.70 | 59.88M | 0 | -10.31M | -12.65M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.61 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
GRCE SEC FilingsGrace Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GRCE: IV nimodipine shows superior efficacy and compliance over oral forms for aSAH treatment - TradingView
Institution Moves: What is Grace Therapeutics Incs valuation compared to sector2025 Trade Ideas & Safe Entry Zone Tips - baoquankhu1.vn
Is OXLC.G forming a breakout patternPortfolio Performance Report & Free Daily Entry Point Trade Alerts - mfd.ru
Rate Hike: Can Grace Therapeutics Inc weather a recessionProfit Target & Reliable Price Action Trade Plans - baoquankhu1.vn
Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update - MarketBeat
ANTX PE Ratio & Valuation, Is ANTX Overvalued - Intellectia AI
PYPD PE Ratio & Valuation, Is PYPD Overvalued - Intellectia AI
GRCE Should I Buy - Intellectia AI
Buy Signal: Is MSAI forming a breakout pattern2025 Trading Volume Trends & Expert Approved Momentum Ideas - baoquankhu1.vn
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - Bitget
Grace CEO joins TD Cowen event with IV nimodipine program - Stock Titan
Stop Loss: Does CRVS stock benefit from AI growthWeekly Trade Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
NVIDIA Corporation (NVDA) to Supply Standalone Grace CPUs in Landmark Data Center Rollout - Yahoo Finance
Companies Like Grace Therapeutics (NASDAQ:GRCE) Are In A Position To Invest In Growth - Sahm
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica
ADAR1 discloses 9.9% Grace Therapeutics (GRCE) ownership in 13G/A - Stock Titan
Aug PreEarnings: Is Grace Therapeutics Inc a turnaround storyMarket Risk Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
SAPMY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Can MetaVia Inc. stock outperform in a bear marketTreasury Yields & Proven Capital Preservation Methods - mfd.ru
Will Grace Therapeutics Inc. stock sustain high P E ratios2025 Technical Patterns & Daily Growth Stock Investment Tips - mfd.ru
Does Grace Therapeutics Inc. have a sustainable dividend2025 Volume Leaders & Real-Time Volume Surge Alerts - mfd.ru
Is EVGOW stock a top momentum playPortfolio Update Report & Daily Entry Point Alerts - mfd.ru
Is SFYX stock good for wealth creation2025 Price Momentum & Real-Time Volume Analysis - mfd.ru
GRCE PE Ratio & Valuation, Is GRCE Overvalued - Intellectia AI
BOL.ST Should I Buy - Intellectia AI
Analysts Are Bullish on Top Healthcare Stocks: Grace Therapeutics (GRCE), Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Is Grace Therapeutics Inc. still a buy after recent gainsWeekly Trading Summary & Technical Pattern Alert System - mfd.ru
Nantahala discloses 9.99% Grace Therapeutics (NASDAQ: GRCE) stake - Stock Titan
Grace Therapeutics announces third quarter 2026 financial results, provides business update - marketscreener.com
Grace Therapeutics (NASDAQ:GRCE) Announces Earnings Results - MarketBeat
Grace Therapeutics (GRCE) Advances Towards FDA Review with Promi - GuruFocus
Is Grace Therapeutics Inc. a cyclical or defensive stockWeekly Stock Summary & Accurate Trade Setup Notifications - mfd.ru
Grace: Fiscal Third Quarter Earnings Overview - Bitget
Grace: Fiscal Q3 Earnings Snapshot - kare11.com
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Q3 2026 Financial Results and Business Update - TradingView
April 23 FDA target date set for Grace’s GTx-104 aSAH drug - Stock Titan
Grace Therapeutics, Inc. SEC 10-Q Report - TradingView
Why is Grace Therapeutics Inc. stock going upShort Setup & Verified Trade Idea Suggestions - mfd.ru
Jobs Data: Can Grace Therapeutics Inc weather a recession2025 Sector Review & Expert-Curated Trade Recommendations - baoquankhu1.vn
Aug Selloffs: What are the risks of holding BioXcel Therapeutics Inc.Weekly Volume Report & Consistent Growth Stock Picks - mfd.ru
Grace Therapeutics (GRCE) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Volatility Watch: Can SolarBank Corporation generate free cash flowJuly 2025 Opening Moves & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Aug Fed Impact: Why is Grace Therapeutics Inc stock going upMarket Trend Review & Smart Allocation Stock Tips - baoquankhu1.vn
Quarterly Recap: Does IMMR stock benefit from AI growthMarket Growth Review & Fast Momentum Entry Tips - baoquankhu1.vn
Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Up 34.6% in January - MarketBeat
Dividend Watch: Is ETRACS 2xMonthly Pay Leveraged Index ETN benefiting from interest rate changesMarket Risk Report & Capital Protection Trade Alerts - baoquankhu1.vn
Gainers Report: Can Grace Therapeutics Inc weather a recessionTake Profit & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
New Highs: Is Grupo Supervielle SA Depositary Receipt a strong candidate for buy and holdJuly 2025 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
What is Chicago Atlantic Real Estate Finance Inc. s 5 year growth outlookJuly 2025 Selloffs & Stepwise Trade Execution Plans - mfd.ru
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):